160 related articles for article (PubMed ID: 15666999)
21. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
[TBL] [Abstract][Full Text] [Related]
22. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
23. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
24. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
[TBL] [Abstract][Full Text] [Related]
25. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
26. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
Casado JA; Río P; Marco E; García-Hernández V; Domingo A; Pérez L; Tercero JC; Vaquero JJ; Albella B; Gago F; Bueren JA
Mol Cancer Ther; 2008 May; 7(5):1309-18. PubMed ID: 18483318
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Martinez EJ; Corey EJ; Owa T
Chem Biol; 2001 Dec; 8(12):1151-60. PubMed ID: 11755394
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
29. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
30. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
31. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
Jin S; Gorfajn B; Faircloth G; Scotto KW
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6775-9. PubMed ID: 10841572
[TBL] [Abstract][Full Text] [Related]
32. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
33. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
[TBL] [Abstract][Full Text] [Related]
34. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
36. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
[TBL] [Abstract][Full Text] [Related]
37. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
Zewail-Foote M; Hurley LH
J Am Chem Soc; 2001 Jul; 123(27):6485-95. PubMed ID: 11439034
[TBL] [Abstract][Full Text] [Related]
38. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters.
Minuzzo M; Ceribelli M; Pitarque-Martì M; Borrelli S; Erba E; DiSilvio A; D'Incalci M; Mantovani R
Mol Pharmacol; 2005 Nov; 68(5):1496-503. PubMed ID: 15961672
[TBL] [Abstract][Full Text] [Related]
39. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
Martínez-Serra J; Maffiotte E; Martín J; Bex T; Navarro-Palou M; Ros T; Plazas JM; Vögler O; Gutiérrez A; Amat JC; Ramos R; Saus C; Ginés J; Alemany R; Diaz M; Besalduch J
Eur J Pharmacol; 2011 May; 658(2-3):57-64. PubMed ID: 21371453
[TBL] [Abstract][Full Text] [Related]
40. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
Soares DG; Escargueil AE; Poindessous V; Sarasin A; de Gramont A; Bonatto D; Henriques JA; Larsen AK
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13062-7. PubMed ID: 17656556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]